Drug General Information (ID: DDIWVJ2FZC)
Drug Name			Bumetanide		Drug Info		Carboplatin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Diuretics				Antineoplastics
Structure

Mechanism of Bumetanide-Carboplatin Interaction (Severity Level: Moderate)
Increased risk of ototoxicity Click to Show/Hide Mechanism Graph
Drug Name		Bumetanide				Carboplatin
Mechanism		Ototoxicity				Ototoxicity
Key Mechanism Factor 1
		Factor Name		Ototoxicity
		Factor Description		Ototoxicity is the damage to the organs of hearing and/or balance following exposure to drugs or chemicals that affect the inner ear. Ototoxic drugs can impair hearing, balance, or both.
Mechanism Description		Increased risk of ototoxicity by the combination of Bumetanide and Carboplatin

Recommended Action
Management		It is recommended to regularly monitor auditory function if concomitant use is necessary. Patients should be advised to promptly notify their physician if they experience hearing loss or tinnitus.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O "Understanding platinum-induced ototoxicity." Trends Pharmacol Sci 34 (2013): 458-69. [PMID: 23769626]
4	Parsons SK, Neault MW, Lehmann, et al "Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma." Bone Marrow Transplant 22 (1998): 669-74. [PMID: 9818694]
5	Product Information. Edecrin (ethacrynic acid). Merck & Co, Inc, West Point, PA.
6	Product Information. Paraplatin (carboplatin). Bristol-Myers Squibb, Princeton, NJ.
7	Brock PR, Knight KR, Freyer DR, et al. "Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale." J Clin Oncol 30 (2012): 2408-17. [PMID: 22547603]